at the end of the day, the NIH grant is a positive (even if it's not a huge amount of money, and is super long-term), and the fact that Arman is officially on board is good news. Also love Lalezari on the PR commenting. these are all examples of things where the company is rebuilding credibility, which was in extremely short supply during NP's tenure.

in terms of raising more $ / dilution, they basically laid that out for us on the call - so i can't see how that's a surprise.

i continue to think / hope that we get this hold lifted by the Fall, and at that point we'll see some sort of catalyst for the SP. until then, i would imagine we bounce around in the 40s.